Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.97K
-0.63%+6.63%+27.22%+16.04% 233B
-1.52%+6.36%+3.75%-15.01% 154B
-0.72%-3.57%-19.65%+31.77% 134B
-2.43%-4.65%-53.34%-2.76% 73B
+0.47%+3.56%-15.04%-11.66% 52.24B
+1.41%-0.21%+12.07%+20.81% 51.75B
-3.72%+2.99%+28.31%+27.95% 44.91B
-0.68%-0.10%+36.26%+50.22% 40.35B
-0.90%+2.28%-0.76%+8.17% 33.8B
Average -0.87%+1.86%+2.09%+13.95% 90.71B
Weighted average by Cap. -0.96%+3.06%+3.59%+11.64%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
7
  1. Stock Market
  2. Stocks
  3. SCIE Stock